Novo Nordisk (NVO.US) Q3 2026 Earnings Call

Live time: 11/04/2026 12:00:00 UTC

诺和诺德公司 (NVO.US) 2026 年第三季度业绩电话会

Summary

00:43
Opening Remarks by Michael Novod
Michael Novod, Head of Investor Relations, opens Novo Nordisk's Q3 2026 earnings call, introduces the key speakers including CEO Mike Duster, CFO Carsten Knussen, and other senior executives. The conference will include forward-looking statements and be followed by a Q&A session.
04:02
CEO Mike Duster Business Update
CEO Mike Duster outlines Novo Nordisk's 2030 goals during the September Capital Markets Day, targeting mid-single-digit compound annual sales growth during 2026–2030. Key commitments include expanding R&D pipelines, promoting sustainable growth, and creating shareholder value. Updates include seven human trials launched and significant advancements in GLP-1 medication for diabetes and obesity treatment.
05:07
Clinical Trials and Market Expansion Update
Novo Nordisk reports treating 48 million people globally with its diabetes and obesity medications, including 5.6 million for obesity. Sales in the obesity segment grew by 22% in Q3, driven by innovations like Wegovy pills and Wegovy HD. The company achieved 32 billion DKK in adjusted operating profit and upgraded its sales guidance for 2026.
09:06
Global Expansion of Oral Obesity Medication
Novo Nordisk expanded its oral obesity medication, Viggo Pill, to seven new markets including France and Mexico and plans to reach over 20 markets by mid-2027. Early feedback from the UK shows a 90% market share in oral obesity treatments.
13:38
R&D Pipeline Highlights by Martin Hertz Lange
CFO Martin Hertz Lange highlights clinical advancements including REIMAGINE5 Phase III trial in type 2 diabetes and REDEFINE9 study in obesity, showcasing promising weight loss among trial participants. Plans to advance treatments like oral zenagantide and denezemic are also detailed.
21:04
CFO Carsten Knussen Financial Overview
CFO Carsten Knussen reports a 4% revenue increase in Q3 2026 to DKK 79.2 billion. Adjusted operating profit grew by 27%, reflecting GLP-1 segment strength. Novo Nordisk upgraded guidance for annual sales growth to -2% to +2%, citing improved market penetration for GLP-1 therapies.
23:33
Future Product Launches by CEO Mike Duster
CEO Mike Duster previews potential launches of FreeHEMGO for hemophilia and CagriSema for obesity in 2027, emphasizing the strategic focus on innovative, patient-centered solutions.
27:55
Q&A Session Start
Michael Novod moderates the Q&A session where analysts inquire about product approvals, 2027 growth outlook, GLP-1 pricing dynamics, and clinical trial updates.

Related Notices

Risk Disclaimer: The content on this page represents the author's personal opinions for general information purposes only and should not be used as a basis for any specific investment, business or commercial decision. It does not represent the position of Longbridge, and the platform makes no guarantees or commitments regarding the authenticity, accuracy or originality of the above content.